오피오이드 사용 장애(OUD) 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측(약제 유형별, 투여 경로별, 유통 채널별, 지역별), 경쟁 구도(2021-2031년)

The Global Opioid Use Disorder (OUD) Drugs Market is projected to expand robustly from USD 3.89 Billion in 2025 to USD 6.81 Billion by 2031, at a Compound Annual Growth Rate of 9.78%. This market encompasses pharmaceutical formulations like buprenorphine, methadone, and naltrexone, which are vital for managing opioid dependence by alleviating withdrawal symptoms and reducing cravings. Market growth is primarily driven by the escalating prevalence of opioid addiction, coupled with substantial increases in government funding dedicated to medication-assisted treatment (MAT) programs. The urgent need for effective therapeutic interventions is underscored by statistics showing a 536 percent rise in workplace overdose fatalities since 2011 by 2026. Moreover, the expanding adoption of evidence-based MAT models, combining behavioral therapy with pharmacotherapy, has significantly propelled demand, leading to over 650,000 individuals receiving OUD medications and contributing to a provisional 27 percent decrease in annual drug overdose deaths in the U.S. by 2024, emphasizing the market's critical role in public health improvement.

Market Driver

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Challenge

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Trends

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Key Market Players

• Indivior PLC
• Alkermes plc
• Braeburn Pharmaceuticals, Inc.
• Novartis AG
• Purdue Pharma L.P.
• Mallinckrodt Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Lundbeck A/S
• Titan Pharmaceuticals, Inc.

Report Scope

In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opioid Use Disorder Drugs Market, By Drug Type

• Agonist Drugs
• Antagonist Drugs
• Others

Opioid Use Disorder Drugs Market, By Route of Administration

• Oral
• Parenteral
• Sublingual
• Nasal

Opioid Use Disorder Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Opioid Use Disorder Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.

Available Customizations:

Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opioid Use Disorder Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
  • 5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Opioid Use Disorder Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Opioid Use Disorder Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Opioid Use Disorder Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Opioid Use Disorder Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Opioid Use Disorder Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Opioid Use Disorder Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Opioid Use Disorder Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Opioid Use Disorder Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Opioid Use Disorder Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Opioid Use Disorder Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Opioid Use Disorder Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Opioid Use Disorder Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Opioid Use Disorder Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Opioid Use Disorder Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Opioid Use Disorder Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Opioid Use Disorder Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Opioid Use Disorder Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Opioid Use Disorder Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Opioid Use Disorder Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Indivior PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Alkermes plc
• 15.3. Braeburn Pharmaceuticals, Inc.
• 15.4. Novartis AG
• 15.5. Purdue Pharma L.P.
• 15.6. Mallinckrodt Pharmaceuticals
• 15.7. Johnson & Johnson Services, Inc.
• 15.8. Pfizer Inc.
• 15.9. Lundbeck A/S
• 15.10. Titan Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer